{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,21]],"date-time":"2026-08-21T13:26:49Z","timestamp":1787318809066,"version":"build-2736575974"},"reference-count":27,"publisher":"Public Library of Science (PLoS)","issue":"8","license":[{"start":{"date-parts":[[2017,8,10]],"date-time":"2017-08-10T00:00:00Z","timestamp":1502323200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"Marie Curie Innovative Training Network (ITN), ADVance","award":["FP7-290002"],"award-info":[{"award-number":["FP7-290002"]}]}],"content-domain":{"domain":["www.plosone.org"],"crossmark-restriction":false},"short-container-title":["PLoS ONE"],"DOI":"10.1371\/journal.pone.0182715","type":"journal-article","created":{"date-parts":[[2017,8,10]],"date-time":"2017-08-10T13:39:45Z","timestamp":1502372385000},"page":"e0182715","update-policy":"https:\/\/doi.org\/10.1371\/journal.pone.corrections_policy","source":"Crossref","is-referenced-by-count":36,"title":["Toxicological and bio-distribution profile of a GM-CSF-expressing, double-targeted, chimeric oncolytic adenovirus ONCOS-102 \u2013 Support for clinical studies on advanced cancer treatment"],"prefix":"10.1371","volume":"12","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-1887-6361","authenticated-orcid":true,"given":"Lukasz","family":"Kuryk","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lotta","family":"Vassilev","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tuuli","family":"Ranki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Akseli","family":"Hemminki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aila","family":"Karioja-Kallio","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Onerva","family":"Lev\u00e4lampi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antti","family":"Vuolanto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vincenzo","family":"Cerullo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sari","family":"Pesonen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"340","published-online":{"date-parts":[[2017,8,10]]},"reference":[{"issue":"9","key":"ref1","doi-asserted-by":"crossref","first-page":"2327","DOI":"10.1158\/0008-5472.CAN-11-2975","article-title":"Immune response is an important aspect of the antitumor effect produced by a CD40L-encoding oncolytic adenovirus","volume":"72","author":"I Diaconu","year":"2012","journal-title":"Cancer research"},{"issue":"7","key":"ref2","doi-asserted-by":"crossref","first-page":"382","DOI":"10.1007\/s002620050590","article-title":"How tumors escape immune destruction and what we can do about it","volume":"48","author":"E Gilboa","year":"1999","journal-title":"Cancer Immunology, Immunotherapy"},{"issue":"10","key":"ref3","doi-asserted-by":"crossref","first-page":"1874","DOI":"10.1038\/mt.2010.161","article-title":"Treatment of cancer patients with a serotype 5\/3 chimeric oncolytic adenovirus expressing GMCSF","volume":"18","author":"A Koski","year":"2010","journal-title":"Molecular therapy: the journal of the American Society of Gene Therapy"},{"issue":"1","key":"ref4","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1021\/mp100219n","article-title":"Oncolytic adenoviruses for the treatment of human cancer: focus on translational and clinical data","volume":"8","author":"S Pesonen","year":"2011","journal-title":"Molecular pharmaceutics"},{"issue":"7","key":"ref5","doi-asserted-by":"crossref","first-page":"892","DOI":"10.1038\/gt.2010.17","article-title":"Prolonged systemic circulation of chimeric oncolytic adenovirus Ad5\/3-Cox2L-D24 in patients with metastatic and refractory solid tumors","volume":"17","author":"S Pesonen","year":"2010","journal-title":"Gene therapy"},{"issue":"1","key":"ref6","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1034\/j.1600-065X.2002.18813.x","article-title":"GM-CSF-based cancer vaccines","volume":"188","author":"G Dranoff","year":"2002","journal-title":"Immunological Reviews"},{"issue":"15","key":"ref7","doi-asserted-by":"crossref","first-page":"3383","DOI":"10.1182\/blood-2011-11-370130","article-title":"Regulation of dendritic cell development by GM-CSF: molecular control and implications for immune homeostasis and therapy","volume":"119","author":"L van de Laar","year":"2012","journal-title":"Blood"},{"issue":"10","key":"ref8","doi-asserted-by":"crossref","first-page":"e958937","DOI":"10.4161\/21624011.2014.958937","article-title":"Local treatment of a pleural mesothelioma tumor with ONCOS-102 induces a systemic antitumor CD8+T-cell response, prominent infiltration of CD8+lymphocytes and Th1 type polarization","volume":"3","author":"T Ranki","year":"2014","journal-title":"OncoImmunology"},{"issue":"12","key":"ref9","doi-asserted-by":"crossref","first-page":"921","DOI":"10.1038\/gt.2008.56","article-title":"Changing the adenovirus fiber for retaining gene delivery efficacy in the presence of neutralizing antibodies","volume":"15","author":"M Sarkioja","year":"2008","journal-title":"Gene therapy"},{"issue":"11","key":"ref10","doi-asserted-by":"crossref","first-page":"966","DOI":"10.1002\/jgm.1373","article-title":"Systemic adenoviral gene delivery to orthotopic murine breast tumors with ablation of coagulation factors, thrombocytes and Kupffer cells","volume":"11","author":"A Koski","year":"2009","journal-title":"J Gene Med"},{"issue":"6","key":"ref11","doi-asserted-by":"crossref","first-page":"1042","DOI":"10.1038\/sj.mt.6300162","article-title":"Prostate cancer gene therapy clinical trials","volume":"15","author":"SO Freytag","year":"2007","journal-title":"Molecular therapy: the journal of the American Society of Gene Therapy"},{"issue":"23","key":"ref12","doi-asserted-by":"crossref","first-page":"7375","DOI":"10.1158\/1078-0432.CCR-09-1910","article-title":"Phase I clinical trial of an adenovirus\/prostate-specific antigen vaccine for prostate cancer: safety and immunologic results","volume":"15","author":"DM Lubaroff","year":"2009","journal-title":"Clin Cancer Res"},{"key":"ref13","doi-asserted-by":"crossref","unstructured":"10.1016\/j.athoracsur.2005.01.048.","DOI":"10.1016\/j.athoracsur.2005.01.048"},{"issue":"2","key":"ref14","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1038\/mt.2009.266","article-title":"Current issues and future directions of oncolytic adenoviruses","volume":"18","author":"M Yamamoto","year":"2010","journal-title":"Molecular therapy: the journal of the American Society of Gene Therapy"},{"key":"ref15","doi-asserted-by":"crossref","first-page":"145","DOI":"10.3389\/fonc.2014.00145","article-title":"Chemotherapy and Oncolytic Virotherapy: Advanced Tactics in the War against Cancer","volume":"4","author":"A Nguyen","year":"2014","journal-title":"Front Oncol"},{"issue":"4","key":"ref16","doi-asserted-by":"crossref","first-page":"945","DOI":"10.1002\/ijc.29048","article-title":"Oncolytic adenovirus and doxorubicin-based chemotherapy results in synergistic antitumor activity against soft-tissue sarcoma","volume":"136","author":"M Siurala","year":"2015","journal-title":"International journal of cancer Journal international du cancer"},{"issue":"6","key":"ref17","doi-asserted-by":"crossref","first-page":"1212","DOI":"10.1038\/mt.2013.51","article-title":"Oncolytic adenovirus with temozolomide induces autophagy and antitumor immune responses in cancer patients","volume":"21","author":"I Liikanen","year":"2013","journal-title":"Molecular therapy: the journal of the American Society of Gene Therapy"},{"issue":"01","key":"ref18","doi-asserted-by":"crossref","DOI":"10.1055\/s-0034-1397203","article-title":"Virotherapy overcomes tumor resistance to PD-1-immunotherapy by broad mutanome-directed T cell responses in mice","volume":"53","author":"N Woller","year":"2015","journal-title":"Zeitschrift f\u00fcr Gastroenterologie"},{"issue":"11","key":"ref19","doi-asserted-by":"crossref","first-page":"1881","DOI":"10.1038\/mt.2014.188","article-title":"How to train your oncolytic virus: the immunological sequel","volume":"22","author":"RG Vile","year":"2014","journal-title":"Molecular therapy: the journal of the American Society of Gene Therapy"},{"issue":"3","key":"ref20","doi-asserted-by":"crossref","first-page":"262","DOI":"10.1016\/j.radonc.2011.05.078","article-title":"Oncolytic viruses in radiation oncology","volume":"99","author":"Y Touchefeu","year":"2011","journal-title":"Radiother Oncol"},{"issue":"7","key":"ref21","doi-asserted-by":"crossref","first-page":"e1017702","DOI":"10.1080\/2162402X.2015.1017702","article-title":"Repeated intratumoral administration of ONCOS-102 leads to systemic antitumor CD8 T-cell response and robust cellular and transcriptional immune activation at tumor site in a patient with ovarian cancer","volume":"4","author":"L Vassilev","year":"2015","journal-title":"Oncoimmunology"},{"issue":"3","key":"ref22","doi-asserted-by":"crossref","first-page":"1270","DOI":"10.1158\/0008-5472.CAN-05-3497","article-title":"Syrian hamster as a permissive immunocompetent animal model for the study of oncolytic adenovirus vectors","volume":"66","author":"MA Thomas","year":"2006","journal-title":"Cancer research"},{"issue":"10","key":"ref23","doi-asserted-by":"crossref","first-page":"746","DOI":"10.1038\/sj.gt.3301424","article-title":"Intravenous infusion of a replication-selective adenovirus (ONYX-015) in cancer patients: safety, feasibility and biological activity","volume":"8","author":"J Nemunaitis","year":"2001","journal-title":"Gene therapy"},{"key":"ref24","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1038\/sj.gt.3301377","article-title":"Clinical research results with dl1520 (Onyx-015), a replication-selective adenovirus for the treatment of cancer: what have we learned?","volume":"8","author":"D Kirn","year":"2001","journal-title":"Gene therapy"},{"issue":"12","key":"ref25","doi-asserted-by":"crossref","first-page":"6291","DOI":"10.3390\/v7122938","article-title":"Evidence for Oncolytic Virotherapy: Where Have We Got to and Where Are We Going?","volume":"7","author":"S Turnbull","year":"2015","journal-title":"Viruses"},{"issue":"5","key":"ref26","doi-asserted-by":"crossref","first-page":"1056","DOI":"10.1038\/mt.2014.21","article-title":"Phase 1 clinical trial of intratumoral reovirus infusion for the treatment of recurrent malignant gliomas in adults","volume":"22","author":"KP Kicielinski","year":"2014","journal-title":"Molecular therapy: the journal of the American Society of Gene Therapy"},{"issue":"1","key":"ref27","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1097\/PPO.0b013e31824671c9","article-title":"Oncolytic virus therapy for glioblastoma multiforme: concepts and candidates","volume":"18","author":"G Wollmann","year":"2012","journal-title":"Cancer J"}],"container-title":["PLOS ONE"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/dx.plos.org\/10.1371\/journal.pone.0182715","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,10,2]],"date-time":"2019-10-02T03:28:13Z","timestamp":1569986893000},"score":1,"resource":{"primary":{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0182715"}},"subtitle":[],"editor":[{"given":"Rudolf","family":"Kirchmair","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"editor"}]}],"short-title":[],"issued":{"date-parts":[[2017,8,10]]},"references-count":27,"journal-issue":{"issue":"8","published-online":{"date-parts":[[2017,8,10]]}},"URL":"https:\/\/doi.org\/10.1371\/journal.pone.0182715","relation":{},"ISSN":["1932-6203"],"issn-type":[{"value":"1932-6203","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,8,10]]}}}